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Huntington’s disease is one of nine neurodegenerative diseases caused by a
polyglutamine (polyQ)-repeat expansion. An anti-polyQ antigen-binding
fragment, MW1 Fab, was crystallized both on Earth and on the International
Space Station, a microgravity environment where convection is limited. Once
the crystals returned to Earth, the number, size and morphology of all crystals
were recorded, and X-ray data were collected from representative crystals. The
results generally agreed with previous microgravity crystallization studies. On
average, microgravity-grown crystals were 20% larger than control crystals
grown on Earth, and microgravity-grown crystals had a slightly improved
mosaicity (decreased by 0.03) and diffraction resolution (decreased by 0.2 A˚)
compared with control crystals grown on Earth. However, the highest resolution
and lowest mosaicity crystals were formed on Earth, and the highest-quality
crystal overall was formed on Earth after return from microgravity.
1. Introduction
Huntington’s disease (HD) is a progressive, late-onset
neurodegenerative disease characterized by neuronal death
resulting in choreiform movements, cognitive decline and
behavioral abnormalities (Ross et al., 2014). There is currently
no disease-modifying treatment or cure for HD (Skotte et al.,
2014). HD is found in individuals with an abnormally
expanded N-terminal polyglutamine (polyQ) repeat in
huntingtin, a 350 kDa protein of unknown function. The
length of this polyQ tract influences the mechanisms of
aggregation and associated binding kinetics, with an increasing
propensity for aggregation with increasing polyQ tract length
(Thakur et al., 2009). HD is completely penetrant when the
polyQ repeat expands beyond a 41-glutamine threshold.
However, the mechanism underlying this transition is unclear,
and the relationship between polyQ-mediated aggregation,
cellular toxicity and HD symptoms has not been well char-
acterized. The structure of polyQ with >41 glutamine residues
has been suggested to adopt a new -sheet conformation
(Nagai et al., 2007) or a random-coil conformation (Vitalis et
al., 2008). Several glutamines in nonpathologic polyQ stret-
ches of huntingtin have previously been crystallized as part of
a maltose-binding protein (MPB) fusion protein at 3.5 A˚
resolution (Kim et al., 2009; PDB entries 3io4, 3io6, 3ior, 3iot,
3iou, 3iov and 3iow). In this series of structures, the modeled
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polyQ region was conformationally flexible and was affected
by the conformation of nearby residues. However, in the
absence of an X-ray crystal structure of the entire polyQ-
repeat region, the nature of the expanded polyQ region and
the interactions between mutant polyQ and other proteins are
unclear.
The polyQ repeat in huntingtin is recognized by several
monoclonal anti-polyQ antibodies, including MW1-6 (Ko et
al., 2001), 3B5H10 (Brooks et al., 2004), 1C2 (Lescure et al.,
1994; Trottier et al., 1995) and 1F8 (White et al., 1997; Persi-
chetti et al., 1999), which has been reported to be similar to
1C2 (White et al., 1997). The X-ray crystal structures of the
3B5H10 Fab (PDB entries 3s96 and 4dcq; Peters-Libeu et al.,
2005, 2012), the 1C2 Fab (PDB entries 4isv and 4jj5; Klein et
al., 2013) and the MW1 Fv (PDB entries 2gsg, 2otu and 2otw;
Li et al., 2007) are structurally homologous (Klein et al., 2013).
While each of these antibodies has a different apparent affi-
nity for polyQ, 1C2, 3B5H10 and MW1 all have lambda light
chains, homologous sequences and strong structural similarity
(Klein et al., 2007). Two recent papers reported the
measurement of huntingtin protein in the cerebrospinal fluid
of patients with HD using the MW1 antibody as one of a pair
of antibodies in immunoprecipitation-flow cytometry (South-
well et al., 2015) or FRET (Ross et al., 2014).
Information about the three-dimensional structure of MW1
and its interactions with mutant huntingtin could assist in the
development of polyQ length-based methods for quantitation
of huntingtin in patients with HD in clinical trials (Zuccato
et al., 2010). X-ray crystal structures of the MW1 fragment
variable (Fv; the variable heavy and variable light domains;
VH and VL) alone (PDB entry 2gsg) and in complex with a
GQ10G peptide (PDB entries 2otu and 2otw) (Li et al., 2007)
demonstrated that the polyQ epitope could adopt a linear and
extended conformation within a shallow groove of the MW1
Fv and also demonstrated that the binding epitope for MW1
encompasses 10 glutamines. Major structural changes
occurred in MW1 Fv upon polyQ binding, including move-
ment of amino acids in the third complementarity-determining
regions (CDRs) of the heavy-chain and light-chain variable
domains (CDRH3 and CDRL3) to allow hydrogen-bond
formation between the antigen-binding site and polyQ.
We previously attempted to crystallize huntingtin alone and
in complex with Fabs (antigen-binding fragments) of anti-
polyQ antibodies, including MW1 Fab. While stable complexes
of Fabs with the polyQ-containing N-terminal domain of
huntingtin with 16, 25, 39 and 46 glutamines (HD-16Q, HD-
25Q, HD-39Q and HD-46Q) formed in solution (Owens et al.,
2015), no crystals of huntingtin or of a Fab–huntingtin
complex could be obtained. Crystallization of the polyQ
stretch of huntingtin is particularly challenging owing to
polyQ length-dependent aggregation (Temussi et al., 2003).
Reduced-gravity environments may improve crystal
formation for proteins such as huntingtin that have a
propensity to form a disordered aggregate at high concen-
trations owing to reduction in buoyancy-driven convection.
In low-convection environments, mass transport is primarily
driven by diffusion. Aggregates diffuse more slowly than
monomers; therefore, monomers may have greater access to
the surface of the growing crystal than aggregates in micro-
gravity (McPherson & DeLucas, 2015). Microgravity has led
to improved crystal volume and quality for several proteins
including insulin (Borgstahl et al., 2001; Dong et al., 1999), a
protein that has been used as a model of amyloid formation
(Ivanova et al., 2009), and PPG10, a collagen-like protein with
a polyproline region similar to that flanking the polyQ region
of huntingtin (Vergara et al., 2002). To gain further insight into
the interaction between anti-polyQ Fabs and the polyQ repeat
of huntingtin, we conducted protein-crystallization experi-
ments on the International Space Station (ISS); this provided
an environment where protein crystals could grow undis-
turbed for several months in a microgravity environment.
Crystallization studies in microgravity and parallel ground-
control tests were designed to examine whether we could
generate high-quality crystals of polyQ proteins or crystals of
a polyQ-containing protein in complex with anti-polyQ Fabs.
We were unable to generate crystals of polyQ-containing
proteins on the ISS or in ground controls, but present here a
comparative analysis of MW1 Fab crystals grown in micro-
gravity and on Earth.
2. Methods
2.1. Protein expression and purification
MW1 Fab was purified as described previously (Owens et
al., 2015). Briefly, MW1 Fab was prepared by papain cleavage
of MW1 IgG and protein A affinity chromatography (GE
Healthcare, Little Chalfont, England), with further purifica-
tion by size-exclusion chromatography (SEC; Superdex 200
10/300 GL). Purified protein was stored at 4C in 50 mM Tris
pH 8.0, 150 mM NaCl for up to three months. Other proteins
used in our microgravity crystallization trials included human
huntingtin exon 1-thioredoxin (TRX) fusion proteins (HD-
16Q, HD-25Q, HD-39Q and HD-46Q; Owens et al., 2015;
Bennett et al., 2002), GFP-huntingtin (Sabogal & Rio, 2010)
and the Fab from an MW1-related antibody called 3B5H10
(Miller et al., 2011). The GFP-huntingtin construct was a gift
from Dr Robert Hughes (Buck Institute, Novato, California,
USA). Each of these proteins was purified using Ni2+–NTA
affinity chromatography (GE Healthcare) and SEC (Superdex
200 10/300 or 16/60), flash-frozen and stored at 80C in
50 mM Tris pH 8.0, 150 mM NaCl, with the exception of GFP-
huntingtin, which was stored at 80C in 10 mM HEPES pH
7.5, 50 mM NaCl, 10% glycerol, 0.5 mM tris(2-carboxyethyl)-
phosphine (TCEP), a reducing agent. Purified full-length
huntingtin protein (Seong et al., 2010) was a gift from Dr
IhnSik Seong (Massachusetts General Hospital) and was
stored at 80C in 50 mM Tris pH 8.0, 100 mM NaCl. Protein
concentrations were determined using 280 nm extinction
coefficients of 78 310 M1 cm1 (MW1 Fab), 80 830 M1 cm1
(3B5H10 Fab), 14 180 M1 cm1 (HD-16Q, HD-25Q, HD-39Q
and HD-46Q) and 22 015 M1 cm1 (GFP-huntingtin).
Extinction coefficients were calculated based on the amino-
acid sequence using ProtParam (Gasteiger et al., 2005). A
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bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford,
Illinois, USA) was used to determine the total protein
concentration of full-length huntingtin.
For crystallization of the MW1 Fab alone, the protein was
concentrated to 7 mg ml1 using a centrifugal filter (EMD
Millipore, Darmstadt, Germany). For MW1 Fab/HD-39Q co-
crystallization trials, purified MW1 Fab and HD-39Q were
incubated in a 3:1 molar ratio for at least 1 h at 4C. Crystal-
lization conditions were optimized on Earth prior to micro-
gravity experiments. Initial concentrations for all proteins are
listed in Supplementary Table S1.
2.2. Vapor-diffusion crystallization
Vapor-diffusion protein crystal-growth experiments in
microgravity were performed using the handheld High
Density Protein Crystal Growth (HDPCG) hardware (Fig. 1a)
developed by the Engineering group at the Center for
Biophysical Sciences and Engineering at the University of
Alabama, Birmingham. The handheld HDPCG hardware was
designed to reproduce a sitting-drop or hanging-drop crys-
tallization experiment in a microgravity environment
(DeLucas et al., 2003), and it has been used to crystallize
dozens of proteins on the Space Shuttle and ISS (Abd
Rahman et al., 2015; Krauspenhaar et al., 2002; Ponassi et al.,
2011). Each aluminium handheld HDPCG hardware unit held
five HDPCG sample blocks (Fig. 1b), which were molded from
Zeonor plastic. Each sample block consisted of six individual
growth cells that each contained a single vapor-diffusion
crystal-growth experiment (Fig. 1c). Each growth cell was
isolated by triple O-ring containment.
For the preparation of experiments prior to launch, 2.5 ml
protein solution was mixed with an equal volume of precipi-
tant solution and placed in a 5 ml well in a growth cell. A
separate reservoir in the same growth cell was loaded with
500 ml precipitant solution at the desired final concentration.
The precipitant solution was immobilized in the reservoir
using an insert made of Chromex, a porous absorbent material
composed of ultrahigh-molecular-weight polyethylene (Porex,
Fairburn, Georgia, USA). A total of 120 crystallization
experiments were set up: 60 for microgravity experiments and
60 replicates as ground controls. Initial conditions for all
experiments are listed in Supplementary Table S1. After all
solutions had been loaded, each well was checked to ensure
there were no bubbles and the sample blocks were sealed. Ten
HDPCG sample blocks total were loaded into two handheld
HDPCG hardware units. To prevent movement or mixing of
solutions prior to or during launch, the sample-block barrels
were rotated 90 clockwise to ‘launch configuration’ (Fig. 1d).
For experiment activation in orbit, an astronaut rotated the
sample-block barrels another 90 clockwise using an Activa-
tion Tool (the silver object in Fig. 1a) to establish an air path
between the protein solution in the well and the precipitant
solution in the reservoir (Fig. 1e). After activation, the
experiments were stored undisturbed on the ISS. Initially, the
protein solution contained an insufficient concentration of
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Figure 1
Schematics of the HDPCG device used for microgravity crystallization experiments. (a) Handheld HDPCG assembly, (b) HDPCG sample block, (c)
HDPCG growth cell in loading configuration, (d) HDPCG growth cell in launch configuration, (e) HDPCG growth cell in microgravity crystal-growth
configuration. The scale bar is 5 mm in length.
precipitant for crystallization, but as water vaporized from
the droplet and transferred to the reservoir, the precipitant
concentration in the protein well increased to an optimal level
for crystallization in some experiments. Before return to
Earth, an astronaut resealed the experiment by using the
Activation Tool to rotate the sample-block barrel counter-
clockwise 90 to ‘launch configuration’ to turn the protein
inserts away from the precipitant reservoir.
2.3. Timeline
All protein and precipitant stock solutions were prepared
7–52 d before launch. Proteins, precipitant solutions and other
equipment were transported to the Space Station Processing
Facility, Kennedy Space Center (KSC), Florida between
9 March and 10 April 2014 for transport on SpaceX CRS-3.
Proteins were maintained at 20C (HD-16Q, HD-25Q, HD-
39Q, HD-46Q, GFP-huntingtin and full-length huntingtin)
or 4C (MW1 Fab and 3B5H10 Fab) during transport and
storage. Before launch, flight HDPCG growth cells were
prepared at 4C in a cold room previously used for astronaut
food storage. Owing to launch-vehicle delays immediately
before two launches, all experimental materials were prepared
repeatedly for launch prior to the successful launch on 18
April 2014. After each scrubbed launch, new inserts with fresh
protein were loaded into the HDPCG apparatus to prevent
protein degradation or aggregation. HDPCG sample filling
and hardware integration was completed on 16 April 2014
(Fig. 2). The HDPCG hardware units were turned over to the
ISS Cold Stowage team for integration on 17 April 2014 and
were installed at 4C on the same day in a Double Cold Bag, a
Nomex bag with vacuum insulation panels for passive thermal
insulation (Campana & Melendez, 2011). The phase-change
material Ice Bricks were added to the Double Cold Bag to
maintain a 4C environment for the HDPCG hardware units
prior to launch and during ascent to the ISS.
A total of 60 experimental crystallization trials in two
handheld HDPCG hardware units were launched from Cape
Canaveral, Florida in an unmanned Falcon-9 supply vehicle on
18 April 2014 at 15:25 Eastern Daylight Time (EDT). The
HDPCG hardware units were maintained at 4C in a Double
Cold Bag during flight. The Dragon capsule mounted atop the
Falcon-9 berthed with the ISS on 21 April 2014, the units were
transferred to the ISS and activation was completed by Flight
Engineer Steven Swanson at 06:50 EDT. After activation, the
experiments were placed in a specialized refrigerator–freezer
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Figure 2
Timeline of (a) microgravity and (b) ground-control experiments.
(Minus Eighty Laboratory Freezer for ISS, MELFI) set at 4C.
Crystals were allowed to grow undisturbed in microgravity at
4C for exactly six months (183 d). The CASIS PCG hardware
remained in the MELFI until just prior to unberth of the
SpaceX-4 Dragon vehicle. HDPCG deactivation and transfer
to a Double Cold Bag at 4C for return was completed at 04:34
EDT on 24 October 2014 by Flight Engineer Reid Wiseman.
The deactivated experiments descended to Earth on 25
October 2014 in SpaceX-4. The Dragon capsule landed in the
Pacific Ocean on 25 October 2014 at 15:39 EDT, and the
experiments were handed over for transfer to Caltech in
Pasadena, California at 22:35 EDT on 26 October 2014. A
temperature of 4  2C was maintained during all transport
operations. The HDPCG hardware units were stored and
imaged, and crystals were harvested, in a 4C room. There
were no pre-flight, in-flight or post-flight anomalies.
2.4. Ground control and comparison studies
The results of the microgravity crystallization experiments
were evaluated on Earth using the best crystals that could be
grown in identical conditions to, and using the same hardware
as, the space-flight experiments, which we termed ‘ground
controls’. Ground controls to replicate the conditions in the
space-flight experiments were set up at 4C at Caltech in
HDPCG sample blocks with identical purified proteins,
buffers and precipitant solutions as used for the microgravity
payload. Similar delays between preparation and activation
were used for the ground controls (Fig. 2), with a 7 d delay
overall compared with flight experiments.
2.5. Crystal number, size and morphology analysis
Immediately upon return from the ISS, bright-field images
of all microgravity crystallization wells were manually taken
at 40 magnification on an Olympus SZX16 microscope
(Olympus Corporation, Tokyo, Japan) using a Canon
DS126311 EOS Rebel camera (Canon, Tokyo, Japan). Crystals
were found at the bottom of the wells; thus, the crystals were
in focus at the same depth of field for all wells. The ground-
control wells also were imaged, with an approximately 7 d
delay. Fiji (Schindelin et al., 2012) was used to measure the
long axis and short axis of each crystal using the line tool. The
area of each crystal was calculated both by multiplying the
long and the short axis and by either the polygon selection tool
or a freehand selection tool based on crystal shape. A
MicroRuler (MiTeGen, Ithaca, New York, USA) was used to
scale images in micrometres. Crystal number, morphology and
visible area were recorded. Morphology was judged by the
sharpness of the crystal edges and the shape of the crystal.
Crystals were photographed again five months after return to
Earth to evaluate changes in crystal size and morphology.
After crystals had been harvested for X-ray diffraction data
collection, the remaining crystals were imaged with a Korima
PRS-1000 UV microscope (Korima, Carson, California, USA)
at 25C to distinguish protein crystals from salt crystals based
on tryptophan fluorescence under UV light. Representative
bright-field and UV images of wells containing protein crystals
are shown in Supplementary Figs. S1 and S2, respectively.
Some small crystals seen with UV microscopy were not visible
using bright-field microscopy; size and X-ray diffraction data
were not collected for these crystals.
2.6. Crystallographic data collection and data-quality
analysis
Protein crystals were removed from the HDPCG sample
wells and briefly soaked in mother-liquor solution supple-
mented with 7.5%, 15% and then 30% glycerol before flash-
cooling in liquid nitrogen. X-ray diffraction data were
collected from a total of 155 representative microgravity-
grown and Earth-grown crystals on beamline 12-2 at the
Stanford Synchrotron Radiation Lightsource (SSRL) using a
PILATUS 6M pixel detector (Dectris) in top-up mode with an
oscillation angle of 0.15,  = 0.98 A˚ and 500 mA ring current.
Crystal-to-detector distances ranged from 270 to 800 mm.
X-ray diffraction data sets were collected for 32 crystals.
X-ray diffraction data were unobtainable for some small
crystals grown in microgravity owing to technical limitations.
The collected data sets were indexed, integrated and scaled
using XDS, a crystallographic data-processing program
(Kabsch, 2010a,b).
Data quality was analyzed using XDS and the PHENIX
crystallography package (Adams et al., 2010). The overall
resolution limits of each data set were estimated using I/(I) >
1.50 as well as CC1/2 (the correlation coefficient between two
random halves of the data set; Karplus & Diederichs, 2012),
where CC1/2 > 0.3. The average mosaicity was determined
using the scaling program AIMLESS (Evans & Murshudov,
2013).
3. Results
3.1. MW1 Fab crystals formed in microgravity had increased
size and decreased abundance compared with crystals grown
on Earth, while their morphology remained similar
Crystals formed in several wells both in microgravity and on
Earth. All crystals formed in wells containing MW1 Fab alone
or MW1 Fab with HD-39Q. No crystals were observed in any
wells containing full-length huntingtin or GFP-huntingtin;
instead, the presence of UV-fluorescent aggregate was noted
in these wells. Crystals were observed in ten of 60 wells in the
microgravity HDPCG wells and in nine of 60 wells in the
ground-control HDPCG wells (Fig. 3a, Table 1). Of the wells
containing crystals, one was found only in the flown samples,
i.e. there were no crystals in the corresponding ground-control
well. This well contained needle crystals that did not diffract
beyond 5 A˚ resolution. No crystals were observed in the
ground-control wells without also being observed in the
sample wells in the flown HDPCG growth cells.
The morphologies of crystals tended to be similar in
microgravity and corresponding ground-control wells. Most
crystals had sharp edges, although several wells contained
crystals with plate or needle morphologies (Fig. 3a). In wells 1
and 2, crystals grown in microgravity were larger and thicker
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than the crystals in parallel ground-control wells (Supple-
mentary Fig. S2). Also, in well 29, ground-control samples
grew only microcrystals from which no diffraction data could
be collected, while crystals were larger in the ISS samples and
diffraction data could be recorded. Conversely, crystals in well
35 grew larger on Earth than in microgravity, demonstrating
that the size effect was not consistent between microgravity
and Earth conditions. Microgravity-induced changes in crystal
morphology have previously been reported (Takahashi et al.,
2013; Zo¨rb et al., 2002; Snell et al., 1997; Savino & Monti,
1996); however, the morphologies that were observed in our
experiments have all been observed previously for analogous
crystals on Earth and did not represent new crystal forms.
Quantitative analyses of crystal number and visible crystal
area from microscopy images demonstrated that fewer crystals
of a size suitable for diffraction (>20 mm in each visible
dimension) were grown per well in microgravity compared
with ground controls (Fig. 3b, Table 1). Two wells in each
condition formed microcrystalline precipitate, microcrystals or
stacks of needle crystals; these crystals were not included in
crystal number and size analysis, which could have changed
the data. Microgravity well 10 contained a large stack of
needle crystals (250 crystals with longest edges of >20 mm)
that could not be accurately counted, and microgravity well 35
contained 3000 microcrystals that were below the threshold
of 20 mm in each visible dimension. In ground controls, well
29 contained 46 microcrystals and well 30 contained 230
microcrystals; these also were not included in the analysis.
Analyses of visible crystal area showed that the crystal size
was larger in microgravity (Fig. 3b, Table 1). Area was used for
these analyses because only two dimensions were visible in
each image. The largest microgravity-grown crystal was larger
than the largest ground-control crystal. This agrees with
previous reports of increased crystal size and decreased crystal
number in microgravity (Abd Rahman et al., 2015). Buoyancy-
induced convection on Earth may increase the rate of
nucleation in solutions containing crystals that are growing,
termed secondary crystal nucleation, owing to a flow of
partially nucleated proteins from growing crystal surfaces
(Snell & Helliwell, 2005). Increased secondary nucleation
would theoretically yield more and smaller crystals on Earth
compared with microgravity, which is consistent with our
findings.
We recorded images of crystals immediately upon receipt of
experiments from the ISS, but no photographs of crystals
could be taken in orbit during microgravity crystal growth
owing to the incompatibility of the current ISS microscope
hardware with the HDPGC growth cells, in particular owing to
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Figure 3
Comparison of crystal morphology and size. Each data point represents a one crystal.. Protein crystals grew in both microgravity and ground-control
conditions. (a) Morphology of crystals and number of wells containing crystals. Wells 1–5 were set up with MW1 or 3B5H10 Fab, wells 6–10 with Fab +
peptide, wells 11 and 12 with HD-16Q, wells 13–22 with Fab + HD-16Q, wells 23–36 with Fab + HD-39Q, wells 37–48 with HD-16Q, HD-25Q, HD-36Q or
HD-46Q, wells 49–54 with huntingtin-GFP and wells 55–60 with full-length huntingtin. See Supplementary Table S1 for a complete description of the
initial conditions. (b) Area of crystals greater than 400 mm2 grown in microgravity (n = 67) and on Earth (n = 97). Data shown are geometric means with
95% confidence intervals. The geometric mean is suitable for data that range over several orders of magnitude (West et al., 2010).
Table 1
Comparison of crystal number and size.
Environment of crystals No. of wells with crystals Average No. of crystals per well† (range) Mean crystal area‡ (mm2) Largest crystal (mm2)
Microgravity 10 7 (5–13) 1840 42700
Ground control 9 14 (1–49) 1500 27200
† Average number of crystals >400 mm2 per well containing crystals. ‡ Geometric mean area.
the variable opacity of the Chromex insert. To keep ground
controls matched to microgravity experiments, ground
controls were also not imaged during the six-month duration
of the experiment. Thus, the optimal time for crystal nuclea-
tion and growth in microgravity is unclear. A different time
frame may have produced more or larger crystals. Addition-
ally, we found that crystals grew several months after return to
Earth in two wells sent to the ISS that did not contain visible
crystals upon initial return to Earth, and three-dimensional
crystal growth also occurred in one well that had only irre-
gularly shaped crystals upon initial return to Earth. This was
confirmed by analysis of a second set of images taken of all
crystallization wells five months after the experiment returned
to Earth. Although crystal nucleation may have taken place on
the ISS, we have categorized these as ‘ground’ crystals in
Table 2 because most crystal growth occurred in a 1g envir-
onment. These ground crystals were not included in
morphology, size or number analyses, but X-ray diffraction
data were collected from several of these crystals.
3.2. Microgravity-grown crystals showed improved X-ray
diffraction resolution on average, but the highest resolution
and lowest mosaicity crystals grew on Earth
Diffraction from microgravity and ground crystals was
evaluated for resolution limit and mosaicity. High resolution is
desirable to allow interpretation of the chemical details of a
protein structure. Mosaicity is defined as the full-width at half-
maximum of diffraction peaks. High average mosaicity values
are a sign of a poorly ordered crystal and are generally
undesirable because larger diffraction maxima can result in
overlapping reflections. However, assessing mosaicity differ-
ences between crystals can be difficult owing to the require-
ment for the use of X-ray beams that have been conditioned
to minimize spectral and geometric effects on the diffraction
maxima.
MW1 was the only protein that crystallized in our experi-
ments. MW1 Fab crystals were obtained in three space groups
(Table 2). Crystals of MW1 Fab alone (space group P21, unit-
cell parameters a = 42, b = 72, c = 89 A˚,  = 91, one molecule
per asymmetric unit) were obtained upon mixing MW1 Fab at
7 mg ml1 with 0.1 M sodium citrate tribasic dihydrate pH 5.0,
18%(w/v) PEG 20 000. This condition yielded crystals that
diffracted to 1.6–2.3 A˚ resolution, the highest resolution of
any MW1 Fab crystals. These crystals formed after return from
the ISS. Crystals that diffracted to 3.0 A˚ resolution were
obtained in this space group and unit cell by mixing MW1 Fab
at 7 mg ml1 plus HD-16Q at 7 mg ml1 with 0.2 M magne-
sium chloride hexahydrate, 0.1 M sodium citrate tribasic
dihydrate pH 5.0, 10%(w/v) PEG 20 000 at 4C, also in a well
where crystal formation occurred after return from the ISS.
Crystals did not form in microgravity or in ground controls in
space group P21, so the effect of microgravity on MW1 Fab
crystals in this space group is unclear.
Crystals of MW1 Fab alone in a second space group
(P212121, unit-cell parameters a = 442 b = 71, c = 208 A˚, one
molecule per asymmetric unit) were obtained upon mixing
MW1 Fab at 7 mg ml1 plus HD-39Q with one of four
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Table 2
X-ray data-processing statistics for MW1 Fab crystals that diffracted to <5.0 A˚ resolution.
Overall resolution limit (A˚) Unit-cell parameters
Environment of crystals Well CC1/2 > 0.3 hI/(I)i† > 1.50 Average mosaicity () a (A˚) b (A˚) c (A˚)  ()  ()  () Space group
Microgravity 29 2.47 2.68 0.08 42.10 71.20 207.72 90 90 90 P212121
Microgravity 34 2.55 2.67 0.13 42.35 71.31 207.31 90 90 90 P212121
Microgravity 34 2.57 2.71 0.07 42.36 71.38 207.31 90 90 90 P212121
Microgravity 34 2.58 2.68 0.13 42.59 71.60 208.37 90 90 90 P212121
Microgravity 29 2.63 2.83 0.07 41.98 71.63 207.64 90 90 90 P212121
Microgravity 34 2.63 2.81 0.18 42.60 71.55 208.62 90 90 90 P212121
Microgravity 29 2.67 2.68 0.11 42.05 71.39 207.72 90 90 90 P212121
Microgravity 1 3.20 3.35 0.12 189.07 189.07 64.37 90 90 120 P622
Ground‡ 2 1.59 1.71 0.06 42.28 71.62 89.19 90 91.51 90 P21
Ground‡ 2 1.65 1.80 0.26 42.21 72.19 89.92 90 91.95 90 P21
Ground‡ 2 1.72 1.80 0.19 42.19 71.53 89.08 90 90.96 90 P21
Ground‡ 2 1.87 2.03 0.09 42.23 71.69 89.05 90 91.39 90 P21
Ground‡ 2 2.19 2.32 0.06 42.19 71.61 88.88 90 91.34 90 P21
Ground‡ 2 2.29 2.61 0.08 42.26 71.70 89.04 90 91.59 90 P21
Ground‡ 17 3.00 3.00 0.15 42.48 72.37 89.78 90 91.43 90 P21
Ground control 27 1.98 2.25 0.10 41.84 70.28 206.78 90 90 90 P212121
Ground control 27 2.13 2.45 0.06 41.94 70.43 207.36 90 90 90 P212121
Ground control 27 2.40 2.69 0.05 42.03 70.50 207.82 90 90 90 P212121
Ground control 35 2.72 2.88 0.07 42.35 71.30 207.37 90 90 90 P212121
Ground control 35 2.76 2.90 0.15 42.31 71.20 207.30 90 90 90 P212121
Ground control 35 2.76 2.95 0.34 42.37 71.10 208.32 90 90 90 P212121
Ground control 35 2.84 2.96 0.17 42.63 71.78 208.79 90 90 90 P212121
Ground control 27 2.89 2.98 0.16 42.22 71.01 208.95 90 90 90 P212121
Ground control 35 2.91 2.96 0.28 42.38 71.29 207.61 90 90 90 P212121
Ground control 27 3.96 3.70 0.06 41.90 70.43 207.75 90 90 90 P212121
Ground control 2 4.05 4.54 0.19 190.64 190.64 64.91 90 90 120 P6222
Ground control 1 4.33 4.07 0.29 323.00 63.74 186.24 90 90 90 P212121
† hI/(I)i is the empirical signal-to-noise ratio (Karplus & Diederichs, 2012). ‡ Visible crystals grew in microgravity wells after return from the ISS.
precipitant solutions at 4C: (i) 0.1 M sodium acetate trihy-
drate pH 4.5, 30%(w/v) PEG 300, (ii) 1.8 M ammonium
sulfate, 0.1 M bis-tris pH 6.5, 2%(v/v) PEG MME 550, (iii)
0.2 M magnesium chloride hexahydrate, 0.1 M sodium citrate
tribasic dihydrate pH 5.0, 14%(w/v) PEG 20 000 or (iv) 0.2 M
magnesium chloride hexahydrate, 0.1 M sodium citrate
tribasic dihydrate pH 5.0, 18%(w/v) PEG 20 000. Over 70% of
crystals that formed in microgravity or ground-control wells
that diffracted to beyond 5.0 A˚ resolution belonged to this
space group and unit cell. The highest resolution crystals in
this space group were formed in ground controls; however, the
average resolution improved by 0.2 A˚ and the average
mosaicity of the diffraction data decreased by 0.03 (not
statistically significant) in microgravity wells compared with
ground-control wells. If the analysis is limited to only crystals
that were looped immediately upon return from the ISS, the
average resolution improved by 0.4 A˚ and the mosaicity
decreased by 0.07 in microgravity wells compared with
ground-control wells. This is consistent with previous findings
of resolution improvements of 0.2–0.4 A˚ for crystals grown in
microgravity compared with ground-control crystals (Strong et
al., 1992).
Crystals of MW1 in a third space group (P622, unit-cell
parameters a = 189, b = 189, c = 64 A˚,  = 120, one molecule
per asymmetric unit) were obtained upon mixing MW1 Fab at
7 mg ml1 with 0.1 M sodium citrate tribasic dihydrate pH 5.5,
16%(w/v) PEG 8000, or 0.1 M sodium citrate tribasic dihy-
drate pH 5.0, 18%(w/v) PEG 20 000 at 4C. Crystals formed
both in microgravity and in ground controls in this space
group; however, the resolution was poor for all diffracting
crystals, ranging from 3.2 A˚ to >8 A˚. The highest resolution
crystals were formed in microgravity, with an improvement of
0.8 A˚ in resolution and a decrease of 0.07 in mosaicity for the
highest resolution microgravity crystal in this space group
compared with the highest resolution ground-control crystal in
the same space group. Ground-control crystals were 7 d
fresher than microgravity crystals when they were cryo-
preserved. Although unlikely over the total course of six
months, it is possible that the results observed may have been
affected by the seven-day difference in the duration of growth.
Previous studies have addressed whether particular space
groups are more amenable to crystallization in a convection-
free environment, and found that no space group appeared to
be more amenable to improvement in microgravity (Judge et
al., 2005). Our results are consistent with this conclusion.
4. Discussion
Microgravity affects crystal growth by decreasing buoyancy-
driven forces on the crystal, thereby creating a more stable
depletion zone around a growing crystal (Snell et al., 2001).
Microgravity also decreases crystal sedimentation, which leads
to fewer fused aggregates and increased uniformity of crystals
(Judge et al., 2005). Through these mechanisms, microgravity-
grown crystals have been reported to have increased resolu-
tion, decreased mosaicity and increased crystal volume
compared with Earth-grown controls (Ng et al., 1997; Barnes
et al., 2002); however, some negative studies have been
published, and the benefit of microgravity crystallization has
been fiercely debated (Stoddard et al., 1992) since the first
microgravity crystallization experiments more than 30 years
ago (Littke & John, 1984).
Here, microgravity was used in an attempt to define the
crystal structure of the polyQ repeat of huntingtin alone or
bound to an anti-polyQ Fab (Hendricks et al., 2009). While
huntingtin was not crystallized in our experiments, crystals of
the anti-polyQ Fab MW1 were readily obtained. Analysis of
microgravity and Earth-grown MW1 Fab crystals showed that
microgravity-grown crystals of MW1 Fab had an increase in
size and an improvement in resolution and mosaicity on
average when compared with Earth-grown crystals in one
space group, in agreement with data published for other
proteins (McPherson & DeLucas, 2015; DeLucas et al., 1986);
however, the highest overall resolution X-ray data in our
experiments were obtained from a crystal grown on Earth
after return from the ISS.
The observed increase in MW1 Fab crystal size in our
microgravity experiments may have been driven by reduced
buoyancy-induced convection in microgravity. However, these
improvements in size may have also been owing in part to
Marangoni convection and transient accelerations, which
promote increases in crystal volume, despite possible dele-
terious effects on crystal packing (Kawaji et al., 2003; Boggon
et al., 1998; Savino & Monti, 1996). Marangoni convection
arises in vapor-diffusion experiments and occurs at the phase
boundary between the concentrated solution of protein and
the air. Concentration gradients that form during crystal-
lization or precipitation result in differences in surface
tension, which lead to different rates of transfer of vapor at the
surface of the protein drop. While Marangoni convection is
not the predominant method of mass transfer in crystallization
experiments on Earth, it becomes an important factor when
buoyancy-induced convection is substantially reduced in
microgravity (Kawaji et al., 2003; Chayen et al., 1997). An
analysis of microgravity experiments found greater improve-
ments in crystal quality (X-ray diffraction resolution, signal-
to-noise ratio and/or mosaicity) in liquid–liquid diffusion
experiments compared with vapor-diffusion experiments
(Judge et al., 2005), which was hypothesized to be owing to
decreased Marangoni convection in liquid–liquid diffusion
compared with vapor-diffusion experiments. Our microgravity
experiments were conducted using the HDPCG vapor-diffu-
sion hardware; it is uncertain how much the use of a liquid–
liquid diffusion apparatus would have impacted our results.
Transient accelerations on the ISS, such as residual accel-
erations from crew movement and exercising, vibrations
imposed by equipment operating near crystallization experi-
ments, and vehicle accelerations from reboost or collision-
avoidance maneuvers (CAMs), could have led to deviation
from a true microgravity environment. In a perfect micro-
gravity environment, crystal nucleation occurs but growth is
slowed because nutrients are depleted in the area of the
crystal–solution interface. Brief accelerations may have stirred
the solutions to replenish nutrients around crystals to help
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them grow larger. Previous research on the Space Shuttle with
continuous visual feedback on crystal growth correlated
increased crystal growth with increases in transient accelera-
tions (Boggon et al., 1998); no similar studies have been
published for microgravity crystallization experiments on the
ISS, so the impact of these transient accelerations is unclear.
While our experiments show that ISS is a potential platform
for crystal growth, crystallization of proteins in space remains
a challenge. Given the expense and time involved in crystal-
lization trials in microgravity, future experiments should
consider the potentially deleterious effects of Marangoni
convection on vapor-diffusion crystallization experiments.
Additionally, a comparison of microgravity-grown crystals
with the best crystals obtainable through ground-based
methods is necessary to realistically determine the relative
value of microgravity protein crystallization.
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